Cargando…

Dynamic Changes in Central and Peripheral Neuro-Injury vs. Neuroprotective Serum Markers in COVID-19 Are Modulated by Different Types of Anti-Viral Treatments but Do Not Affect the Incidence of Late and Early Strokes

The balance between neurodegeneration, neuroinflammation, neuroprotection, and COVID-19-directed therapy may underly the heterogeneity of SARS-CoV-2′s neurological outcomes. A total of 105 patients hospitalized with a diagnosis of COVID-19 had serum collected over a 6 month period to assess neuroinf...

Descripción completa

Detalles Bibliográficos
Autores principales: Laudanski, Krzysztof, Hajj, Jihane, Restrepo, Mariana, Siddiq, Kumal, Okeke, Tony, Rader, Daniel J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8698659/
https://www.ncbi.nlm.nih.gov/pubmed/34944606
http://dx.doi.org/10.3390/biomedicines9121791
_version_ 1784620330010017792
author Laudanski, Krzysztof
Hajj, Jihane
Restrepo, Mariana
Siddiq, Kumal
Okeke, Tony
Rader, Daniel J.
author_facet Laudanski, Krzysztof
Hajj, Jihane
Restrepo, Mariana
Siddiq, Kumal
Okeke, Tony
Rader, Daniel J.
author_sort Laudanski, Krzysztof
collection PubMed
description The balance between neurodegeneration, neuroinflammation, neuroprotection, and COVID-19-directed therapy may underly the heterogeneity of SARS-CoV-2′s neurological outcomes. A total of 105 patients hospitalized with a diagnosis of COVID-19 had serum collected over a 6 month period to assess neuroinflammatory (MIF, CCL23, MCP-1), neuro-injury (NFL, NCAM-1), neurodegenerative (KLK6, τ, phospho τ, amyloids, TDP43, YKL40), and neuroprotective (clusterin, fetuin, TREM-2) proteins. These were compared to markers of nonspecific inflammatory responses (IL-6, D-dimer, CRP) and of the overall viral burden (spike protein). Data regarding treatment (steroids, convalescent plasma, remdasavir), pre-existing conditions, and incidences of strokes were collected. Amyloid β42, TDP43, NF-L, and KLK6 serum levels declined 2–3 days post-admission, yet recovered to admission baseline levels by 7 days. YKL-40 and NCAM-1 levels remained elevated over time, with clusters of differential responses identified among TREM-2, TDP43, and YKL40. Fetuin was elevated after the onset of COVID-19 while TREM-2 initially declined before significantly increasing over time. MIF serum level was increased 3–7 days after admission. Ferritin correlated with TDP-43 and KLK6. No treatment with remdesivir coincided with elevations in Amyloid-β40. A lack of convalescent plasma resulted in increased NCAM-1 and total tau, and steroidal treatments did not significantly affect any markers. A total of 11 incidences of stroke were registered up to six months after initial admission for COVID-19. Elevated D-dimer, platelet counts, IL-6, and leukopenia were observed. Variable MIF serum levels differentiated patients with CVA from those who did not have a stroke during the acute phase of COVID-19. This study demonstrated concomitant and opposite changes in neurodegenerative and neuroprotective markers persisting well into recovery.
format Online
Article
Text
id pubmed-8698659
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-86986592021-12-24 Dynamic Changes in Central and Peripheral Neuro-Injury vs. Neuroprotective Serum Markers in COVID-19 Are Modulated by Different Types of Anti-Viral Treatments but Do Not Affect the Incidence of Late and Early Strokes Laudanski, Krzysztof Hajj, Jihane Restrepo, Mariana Siddiq, Kumal Okeke, Tony Rader, Daniel J. Biomedicines Article The balance between neurodegeneration, neuroinflammation, neuroprotection, and COVID-19-directed therapy may underly the heterogeneity of SARS-CoV-2′s neurological outcomes. A total of 105 patients hospitalized with a diagnosis of COVID-19 had serum collected over a 6 month period to assess neuroinflammatory (MIF, CCL23, MCP-1), neuro-injury (NFL, NCAM-1), neurodegenerative (KLK6, τ, phospho τ, amyloids, TDP43, YKL40), and neuroprotective (clusterin, fetuin, TREM-2) proteins. These were compared to markers of nonspecific inflammatory responses (IL-6, D-dimer, CRP) and of the overall viral burden (spike protein). Data regarding treatment (steroids, convalescent plasma, remdasavir), pre-existing conditions, and incidences of strokes were collected. Amyloid β42, TDP43, NF-L, and KLK6 serum levels declined 2–3 days post-admission, yet recovered to admission baseline levels by 7 days. YKL-40 and NCAM-1 levels remained elevated over time, with clusters of differential responses identified among TREM-2, TDP43, and YKL40. Fetuin was elevated after the onset of COVID-19 while TREM-2 initially declined before significantly increasing over time. MIF serum level was increased 3–7 days after admission. Ferritin correlated with TDP-43 and KLK6. No treatment with remdesivir coincided with elevations in Amyloid-β40. A lack of convalescent plasma resulted in increased NCAM-1 and total tau, and steroidal treatments did not significantly affect any markers. A total of 11 incidences of stroke were registered up to six months after initial admission for COVID-19. Elevated D-dimer, platelet counts, IL-6, and leukopenia were observed. Variable MIF serum levels differentiated patients with CVA from those who did not have a stroke during the acute phase of COVID-19. This study demonstrated concomitant and opposite changes in neurodegenerative and neuroprotective markers persisting well into recovery. MDPI 2021-11-29 /pmc/articles/PMC8698659/ /pubmed/34944606 http://dx.doi.org/10.3390/biomedicines9121791 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Laudanski, Krzysztof
Hajj, Jihane
Restrepo, Mariana
Siddiq, Kumal
Okeke, Tony
Rader, Daniel J.
Dynamic Changes in Central and Peripheral Neuro-Injury vs. Neuroprotective Serum Markers in COVID-19 Are Modulated by Different Types of Anti-Viral Treatments but Do Not Affect the Incidence of Late and Early Strokes
title Dynamic Changes in Central and Peripheral Neuro-Injury vs. Neuroprotective Serum Markers in COVID-19 Are Modulated by Different Types of Anti-Viral Treatments but Do Not Affect the Incidence of Late and Early Strokes
title_full Dynamic Changes in Central and Peripheral Neuro-Injury vs. Neuroprotective Serum Markers in COVID-19 Are Modulated by Different Types of Anti-Viral Treatments but Do Not Affect the Incidence of Late and Early Strokes
title_fullStr Dynamic Changes in Central and Peripheral Neuro-Injury vs. Neuroprotective Serum Markers in COVID-19 Are Modulated by Different Types of Anti-Viral Treatments but Do Not Affect the Incidence of Late and Early Strokes
title_full_unstemmed Dynamic Changes in Central and Peripheral Neuro-Injury vs. Neuroprotective Serum Markers in COVID-19 Are Modulated by Different Types of Anti-Viral Treatments but Do Not Affect the Incidence of Late and Early Strokes
title_short Dynamic Changes in Central and Peripheral Neuro-Injury vs. Neuroprotective Serum Markers in COVID-19 Are Modulated by Different Types of Anti-Viral Treatments but Do Not Affect the Incidence of Late and Early Strokes
title_sort dynamic changes in central and peripheral neuro-injury vs. neuroprotective serum markers in covid-19 are modulated by different types of anti-viral treatments but do not affect the incidence of late and early strokes
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8698659/
https://www.ncbi.nlm.nih.gov/pubmed/34944606
http://dx.doi.org/10.3390/biomedicines9121791
work_keys_str_mv AT laudanskikrzysztof dynamicchangesincentralandperipheralneuroinjuryvsneuroprotectiveserummarkersincovid19aremodulatedbydifferenttypesofantiviraltreatmentsbutdonotaffecttheincidenceoflateandearlystrokes
AT hajjjihane dynamicchangesincentralandperipheralneuroinjuryvsneuroprotectiveserummarkersincovid19aremodulatedbydifferenttypesofantiviraltreatmentsbutdonotaffecttheincidenceoflateandearlystrokes
AT restrepomariana dynamicchangesincentralandperipheralneuroinjuryvsneuroprotectiveserummarkersincovid19aremodulatedbydifferenttypesofantiviraltreatmentsbutdonotaffecttheincidenceoflateandearlystrokes
AT siddiqkumal dynamicchangesincentralandperipheralneuroinjuryvsneuroprotectiveserummarkersincovid19aremodulatedbydifferenttypesofantiviraltreatmentsbutdonotaffecttheincidenceoflateandearlystrokes
AT okeketony dynamicchangesincentralandperipheralneuroinjuryvsneuroprotectiveserummarkersincovid19aremodulatedbydifferenttypesofantiviraltreatmentsbutdonotaffecttheincidenceoflateandearlystrokes
AT raderdanielj dynamicchangesincentralandperipheralneuroinjuryvsneuroprotectiveserummarkersincovid19aremodulatedbydifferenttypesofantiviraltreatmentsbutdonotaffecttheincidenceoflateandearlystrokes